1-4 of 4
Alfred Nordheim, PhD
Close
Sort by
Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD
Journal: Blood
Blood (2006) 108 (11): 1379.
https://doi.org/10.1182/blood.V108.11.1379.1379
Published: 2006
Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD
Journal: Blood
Blood (2005) 106 (11): 1997.
https://doi.org/10.1182/blood.V106.11.1997.1997
Published: 2005
Journal Articles

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Patrick Ziegler, PhD, Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer Kammer, PhD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD
Journal: Blood
Blood (2004) 104 (11): 2944.
https://doi.org/10.1182/blood.V104.11.2944.2944
Published: 2004
Journal Articles

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer, PhD, Patrick Ziegler, PhD, Martin Priemer, Gerold Schwarz, Lothar Kanz, MD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD
Journal: Blood
Blood (2004) 104 (11): 2957.
https://doi.org/10.1182/blood.V104.11.2957.2957
Published: 2004